Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data.

Zimmermann, Frederik M; Omerovic, Elmir; Fournier, Stephane; Kelbæk, Henning; Johnson, Nils P; Rothenbühler, Martina; Xaplanteris, Panagiotis; Abdel-Wahab, Mohamed; Barbato, Emanuele; Høfsten, Dan Eik; Tonino, Pim A L; Boxma-de Klerk, Bianca M; Fearon, William F; Køber, Lars; Smits, Pieter C; De Bruyne, Bernard; Pijls, Nico H J; Jüni, Peter; Engstrøm, Thomas (2019). Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. European Heart Journal, 40(2), pp. 180-186. Oxford University Press 10.1093/eurheartj/ehy812

[img]
Preview
Text
Zimmermann EurJHeart 2019.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (555kB) | Preview

Aims To assess the effect of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) with contemporary drug-eluting stents on the composite of cardiac death or myocardial infarction (MI) vs. medical therapy in patients with stable coronary lesions. Methods and results We performed a systematic review and meta-analysis of individual patient data (IPD) of the three available randomized trials of contemporary FFR-guided PCI vs. medical therapy for patients with stable coronary lesions: FAME 2 (NCT01132495), DANAMI-3-PRIMULTI (NCT01960933), and Compare-Acute (NCT01399736). FAME 2 enrolled patients with stable coronary artery disease (CAD), while the other two focused on non-culprit lesions in stabilized patients after acute coronary syndrome. A total of 2400 subjects were recruited from 54 sites world-wide with 1056 randomly assigned to FFR-guided PCI and 1344 to medical therapy. The pre-specified primary outcome was a composite of cardiac death or MI. We included data from extended follow-ups for FAME 2 (up to 5.5 years follow-up) and DANAMI-3-PRIMULTI (up to 4.7 years follow-up). After a median follow-up of 35 months (interquartile range 12-60 months), a reduction in the composite of cardiac death or MI was observed with FFR-guided PCI as compared with medical therapy (hazard ratio 0.72, 95% confidence interval 0.54-0.96; P = 0.02). The difference between groups was driven by MI. Conclusion In this IPD meta-analysis of the three available randomized controlled trials to date, FFR-guided PCI resulted in a reduction of the composite of cardiac death or MI compared with medical therapy, which was driven by a decreased risk of MI.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > CTU Bern

UniBE Contributor:

Rothenbühler, Martina

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0195-668X

Publisher:

Oxford University Press

Language:

English

Submitter:

Tanya Karrer

Date Deposited:

17 Jan 2019 19:53

Last Modified:

05 Feb 2019 10:48

Publisher DOI:

10.1093/eurheartj/ehy812

PubMed ID:

30596995

BORIS DOI:

10.7892/boris.123516

URI:

https://boris.unibe.ch/id/eprint/123516

Actions (login required)

Edit item Edit item
Provide Feedback